Kymera Therapeutics annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Shares Outstanding History (KYMR)
Kymera Therapeutics reported 81.3M shares outstanding at the end of fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 81.3M | 16.4M | +25.32% |
| 2024 | 2024-12-31 | 64.9M | 9.3M | +16.74% |
| 2023 | 2023-12-31 | 55.6M | 545,925 | +0.99% |
| 2022 | 2022-12-31 | 55.0M | 3.5M | +6.80% |
| 2021 | 2021-12-31 | 51.5M | 7.1M | +15.86% |
| 2020 | 2020-12-31 | 44.5M | 42.6M | +2205.35% |
| 2019 | 2019-12-31 | 1.9M | — | — |
Kymera Therapeutics quarterly shares outstanding
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 82.8M | 12.2M | +17.33% |
| Q1 2026 | 2026-03-31 | 82.2M | 17.1M | +26.22% |
| Q4 2025 | 2025-12-31 | 81.3M | 16.4M | +25.32% |
| Q3 2025 | 2025-09-30 | 71.7M | 7.0M | +10.80% |
| Q2 2025 | 2025-06-30 | 70.6M | 9.0M | +14.59% |
| Q1 2025 | 2025-03-31 | 65.1M | 3.8M | +6.13% |
| Q4 2024 | 2024-12-31 | 64.9M | 9.3M | +16.74% |
| Q3 2024 | 2024-09-30 | 64.7M | 9.3M | +16.77% |
| Q2 2024 | 2024-06-30 | 61.6M | 6.2M | +11.16% |
| Q1 2024 | 2024-03-31 | 61.4M | 6.1M | +10.99% |
| Q4 2023 | 2023-12-31 | 55.6M | 545,925 | +0.99% |
| Q3 2023 | 2023-09-30 | 55.5M | 698,810 | +1.28% |
| Q2 2023 | 2023-06-30 | 55.4M | 3.5M | +6.83% |
| Q1 2023 | 2023-03-31 | 55.3M | 3.6M | +6.93% |
| Q4 2022 | 2022-12-31 | 55.0M | 3.5M | +6.80% |
| Q3 2022 | 2022-09-30 | 54.8M | 3.5M | +6.82% |
| Q2 2022 | 2022-06-30 | 51.8M | 6.5M | +14.38% |
| Q1 2022 | 2022-03-31 | 51.7M | 6.8M | +15.18% |
| Q4 2021 | 2021-12-31 | 51.5M | 7.1M | +15.86% |
| Q3 2021 | 2021-09-30 | 51.3M | 6.8M | +15.32% |
| Q2 2021 | 2021-06-30 | 45.3M | — | — |
| Q1 2021 | 2021-03-31 | 44.9M | — | — |
| Q4 2020 | 2020-12-31 | 44.5M | 42.6M | +2205.35% |
| Q3 2020 | 2020-09-30 | 44.4M | — | — |
| Q4 2019 | 2019-12-31 | 1.9M | — | — |
Kymera Therapeutics shares outstanding trends
Over the last five fiscal years, Kymera Therapeutics's shares outstanding moved from 44.5M to 81.3M, a change of 36.8M. The latest reported quarter, Q2 2026, shows 82.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗Community posts
Kymera reports early human results for oral IRF5 drug
Kymera ($KYMR) reported results from its first human study of KT-579, an experimental oral medicine targeting the immune regulator IRF5. In healthy volunteers receiving repeated doses, median blood IRF5 reductions reached at least 90% acros ...
